AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

Losing U.S. exclusivity in early 2023, Humira, the top-selling arthritis medication from AbbVie, let biosimilars from Amgen ( ...

AbbVie (ABBV) continues to dominate the adalimumab market with 72% share in the U.S., despite biosimilar threats gaining ground. Read more here.

AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations.

Three Motley Fool contributors have identified some especially great high-yield dividend stocks to buy in 2025 -- and all of them are big pharma stocks. Here's why they chose AbbVie(NYSE: ABBV), Amgen ...

Simcere Pharmaceutical said on Monday its unit had granted U.S. drugmaker AbbVie the option to license its new blood cancer ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

Adalimumab and secukinumab are the only FDA-approved biologic drugs to treat hidradenitis suppurativa, limiting options for ...